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Introduction
Neurostimulation is of increasing interest in headache
therapy. Invasive neurostimulation methods were found
effective in drug-refractory headaches. There is a need
for non invasive therapies that could be justified in less
disabled patients. Previous case reports suggested that
internal Vagus Nerve Stimulation (VNS) might be effec-
tive in headache prevention [1-3].
Objectives
We explored efficacy and safety of a transcutaneous VNS
device (tVNS, Gammacore®) as preventive treatment in
primary headache sufferers. The aim of this pilot trial was
to determine a target subpopulation for a multicenter
sham-controlled study.
Methods
Eighteen patients accepted to undertake prophylaxis
with tVNS: 12 migraine without aura patients (MO, 5
with medication overuse, MOH, 3 chronic), 4 patients
with trigeminal autonomic cephalalgia (2 chronic cluster
headache, CCH), and 2 with hemicrania continua (HC).
tVNS was applied 3 times/day during 90 seconds. Data
were collected using headache diaries.
Results
Results are available for 13 patients. Ten patients stopped
tVNS after 0.7 to 6 weeks because of lack of efficacy (N=9)
and/or side effects (N=6). In one patient with CCH,
attacks decreased from 4.5/day to 0.39/day, and in a
patient with MOH headache days decreased from 7/week
to 3/week and intensity from 8.5 to 4/10. The benefit
remains after 5 months of treatment and attack frequency
increases when stimulation is interrupted. The last patient
had HC with initial intensity decrease from 8.5 to 4/10 but
relapsed after 8 weeks. Reported side effects were local
discomfort (N=3), tonic muscle contraction (N=3), fatigue
(N=1), palpitations (N=1) and cervical muscle spasm
(N=1).
Conclusions
Our initial experience suggests that tVNS might help some
headache patients. That it was not effective in many
patients may be due to the fact that the vagus nerve is not
or insufficiently stimulated. There were no serious adverse
events but the stimulation could be poorly tolerated.
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